| abstract |
This refers to a new crystalline form of 4- (5 - {(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4 -triazol-3-yl) pyridine. In addition, this also refers to the use of the new crystalline form for the treatment of gastrointestinal disorders and pharmaceutical compositions containing it. Claim 4: 4- (5 - {(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl ) pyridine in the crystalline form according to claim 1, characterized in that it provides a powder X-ray diffraction pattern that has substantially the following main peak with the values d: Spacing value d (L): 4.0; 5.08; 5.72; 6.21; 6.35; 11.41; 12.63. |